Tessera's Gene Writing platform is designed to write therapeutic messages into the genome by efficiently changing single or multiple DNA base pairs, precisely correcting insertions and deletions, or adding exon-length sequences and whole genes, leveraging a proprietary lipid nanoparticle delivery platform designed to enable the in vivo delivery of RNA to targeted cell types. The company's lead program, TSRA-196, received FDA Fast Track and Orphan Drug designations in February 2026 and is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD).
Cyborg Score Rationale
Tessera benefits from elite backing (Flagship Pioneering), strong capital position (>$500M raised as of April 2022), and a differentiated technology platform addressing limitations of existing gene therapies and editing approaches. Recent FDA regulatory milestones and pharma partnership validate the platform's clinical potential.
Top Insights
FDA cleared the IND application for TSRA-196 in January 2026, followed by Fast Track and Orphan Drug designations in February 2026
TSRA-196 is being jointly developed with Regeneron for AATD and designed to correct the genetic mutation and restore alpha-1 antitrypsin protein production through a one-time, durable treatment
The company raised over $300 million in Series C financing announced in April 2022
Platform addresses key limitations of existing gene therapy and CRISPR editing by writing sequences into the genome rather than cutting or destroying DNA
Named Competitors
CRISPR Gene Editing — CRISPR-based gene editing for genetic diseases